Centre Hospitalier Universitaire Vaudois
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 2008-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.chuv.ch
Clinical Trials
200
Active:6
Completed:101
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:26
Phase 2:10
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (142 trials with phase data)• Click on a phase to view related trials
Not Applicable
81 (57.0%)Phase 1
26 (18.3%)Phase 4
18 (12.7%)Phase 2
10 (7.0%)Phase 3
5 (3.5%)Early Phase 1
2 (1.4%)Deciphering the Mechanisms of Central BP Regulation in Patients With PD Associated With Orthostatic Hypotension
Not yet recruiting
- Conditions
- Parkinson DiseaseOrthostatic Hypotension
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-08-24
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 130
- Registration Number
- NCT07139756
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
Posterior Circulation Clot Burden Score (Pc-CBS) Predicts Clinical Outcome After Acute Ischemic Stroke Related to Posterior Circulation Occlusions : An Externally Validated Radiological Score
Completed
- Conditions
- Acute Ischemic StrokeArterial Occlusion DiseasePosterior Circulation Brain Infarction
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 1828
- Registration Number
- NCT07122934
Comparison of Pericapsular Nerve Group (PENG) Block With a Combined Femoral and Sciatic Nerve Block for Postoperative Analgesia in Secondary Total Hip Arthroplasty; (REVPET)
Not Applicable
Not yet recruiting
- Conditions
- Hip Arthroplasty ReplacementPost Operative AnalgesiaPost Operative Pain, Acute
- Interventions
- Drug: Pericapsular nerve group (PENG) block with 0.75% ropivacaine guided by ultrasoundDrug: Femoral nerve block with 0.375% ropivacaine guided by ultrasound
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 50
- Registration Number
- NCT07109388
68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma
Not Applicable
Not yet recruiting
- Conditions
- Pancreatic AdenocarcinomaPET / CTFAPISurgical OncologyMolecular Imaging
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 20
- Registration Number
- NCT06911021
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Phase 1
Recruiting
- Conditions
- Advanced MelanomaMelanoma MetastaticSarcoma
- Interventions
- Biological: NY-ESO-1 TCR redirected autologous T cell productRadiation: Low-dose irradiationDrug: Non-myeloablative lymphodepleting chemotherapy
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 9
- Registration Number
- NCT06889766
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
🇨🇭Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, VD, Switzerland
- Prev
- 1
- 2
- 3
- 4
- 5
- 40
- Next
News
ONWARD Medical Advances Brain-Computer Interface Technology with Fifth Successful Implant for Spinal Cord Injury Patients
ONWARD Medical has successfully implanted its ARC-BCI® Therapy in two additional patients, bringing the total to five individuals with spinal cord injuries who can now potentially control movement through thought.